Market Cap 121.60B
Revenue (ttm) 47.92B
Net Income (ttm) 6.02B
EPS (ttm) N/A
PE Ratio 12.16
Forward PE 11.13
Profit Margin 12.55%
Debt to Equity Ratio 0.29
Volume 4,635,000
Avg Vol 3,275,164
Day's Range N/A - N/A
Shares Out 2.46B
Stochastic %K 85%
Beta 0.51
Analysts Strong Sell
Price Target $62.94

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande Armée, Paris, France
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 4:50 PM
$SNY beats again — Dupixent is carrying the load 💪 Q3 earnings topped forecasts as Dupixent surged past EUR 4B in sales, more than making up for softness in the vaccine segment. Full breakdown here 👉 https://www.zacks.com/stock/news/2776468/sanofi-q3-earnings-beat-dupixent-drives-growth-as-vaccines-decline?cid=sm-stocktwits-2-2776468-teaser-17564&ADID=SYND_STOCKTWITS_TWEET_2_2776468_TEASER_17564
0 · Reply
smartoptionstrader
smartoptionstrader Oct. 24 at 4:37 PM
MAIN POST: Big Pharma's M&A wave isn't slowing—it's accelerating into 2026. $MRK $JNJ $SNY desperately plugging patent cliff revenue holes. But here's the smarter play: $GS collects fees on every deal. Trading at $781 (15.5x earnings, below $SPY average) and $44 off September highs, Goldman is positioned perfectly. Lower rates, desperate acquirers, and frozen IPOs lead to more deals, resulting in more GS fees. Don't gamble on which biotech gets bought—follow the money to Wall Street's M&A king. Goldman Sachs Long-Term Price Chart (1997-2025) - Shows a steady upward trajectory with a September 2025 record high at $825, currently trading at $781. The chart demonstrates GS's consistent performance across multiple market cycles, validating the bullish technical setup with clear upside potential to new highs.
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:50 PM
$SNY beats Q3 expectations — but why isn't the stock soaring? 🤔 Sanofi's Q3 results showed a 13.2% EPS increase at constant currency, beating the Zacks Consensus Estimate with Dupixent sales hitting over €4B for the first time. Yet, shares are only up 2% in pre-market trading. Discover why the market's lukewarm on SNY despite strong performance 👉 https://www.zacks.com/stock/news/2776468/sanofi-q3-earnings-beat-dupixent-drives-growth-as-vaccines-decline?cid=sm-stocktwits-2-2776468-body-17553&ADID=SYND_STOCKTWITS_TWEET_2_2776468_BODY_17553
0 · Reply
Diapers_Tequila
Diapers_Tequila Oct. 24 at 3:25 PM
$ALT Here is the link for the $SNY call this morning for everyone who missed it. https://www.youtube.com/watch?v=o6p0W4ZsLXw
2 · Reply
Jacked_Nicholson
Jacked_Nicholson Oct. 24 at 1:53 PM
$ALT @Designed2Gain $SNY $ €14-€15B
3 · Reply
GreenEnergy2022
GreenEnergy2022 Oct. 24 at 1:26 PM
$ALT Sounds like $SNY is looking for a best in class investment
1 · Reply
BTC321
BTC321 Oct. 24 at 12:53 PM
$NVAX $NVAX $SNY 🚀 Sanofi just reported strong positive results and mentioned Novavax in the same breath. The combo vaccines Fluzone HD + Nuvaxovid and Flublok + Nuvaxovid are already on the FDA Fast Track (US). 👉 If approved, this would be the first flu + COVID-19 protein vaccine — a potential game changer for both companies. Momentum is building. Volume next. 💥 #NVAX #SNY #FastTrack #Biotech #ShortSqueeze
1 · Reply
OpenOutcrier
OpenOutcrier Oct. 24 at 12:37 PM
$SNY (+2.1% pre) Sanofi (SNY) Tops Q3 EPS by 72c https://ooc.bz/l/81768
0 · Reply
Quantumup
Quantumup Oct. 24 at 11:26 AM
H.C. Wainwright reiterated $CDTX Buy/$150 after at the European Scientific Working Group on Influenza (ESWI)s 10th Influenza Conference, Cidara presented translational efficacy data on CD388, the company's lead influenza drug-Fc conjugate (DFC) candidate. $SNY $JNJ HCW in its note said:
0 · Reply
Latest News on SNY
Sanofi: Is Dupixent Too Successful?

Oct 24, 2025, 2:32 PM EDT - 17 hours ago

Sanofi: Is Dupixent Too Successful?


Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal

Oct 24, 2025, 1:37 PM EDT - 18 hours ago

Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal


Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

Oct 24, 2025, 1:37 PM EDT - 18 hours ago

Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

SAN


Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark

Oct 24, 2025, 10:47 AM EDT - 21 hours ago

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark


Press release: Q3: continued sales and earnings progress

Oct 24, 2025, 1:30 AM EDT - 1 day ago

Press release: Q3: continued sales and earnings progress


ITM Appoints Annette Breunig as Chief People Officer

Oct 13, 2025, 5:00 AM EDT - 12 days ago

ITM Appoints Annette Breunig as Chief People Officer


Sanofi Expands Insulin Savings Program To Cover All US Patients

Sep 26, 2025, 1:40 PM EDT - 4 weeks ago

Sanofi Expands Insulin Savings Program To Cover All US Patients


Sanofi to offer all insulin products for $35 per month in US

Sep 26, 2025, 8:26 AM EDT - 4 weeks ago

Sanofi to offer all insulin products for $35 per month in US


Press release: Availability of the Q3 2025 Aide mémoire

Sep 24, 2025, 1:00 AM EDT - 4 weeks ago

Press release: Availability of the Q3 2025 Aide mémoire


Why Is Sanofi Stock Falling Thursday?

Sep 4, 2025, 2:36 PM EDT - 7 weeks ago

Why Is Sanofi Stock Falling Thursday?


Sanofi Shares Sink as Experimental Drug Results Disappoint

Sep 4, 2025, 4:43 AM EDT - 7 weeks ago

Sanofi Shares Sink as Experimental Drug Results Disappoint


Now Is The Time To Buy This High-Yielding Trio

Aug 30, 2025, 1:24 PM EDT - 7 weeks ago

Now Is The Time To Buy This High-Yielding Trio

AES CMCSA


US FDA approves Sanofi's drug for a rare blood disorder

Aug 29, 2025, 5:56 PM EDT - 2 months ago

US FDA approves Sanofi's drug for a rare blood disorder


BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 4:50 PM
$SNY beats again — Dupixent is carrying the load 💪 Q3 earnings topped forecasts as Dupixent surged past EUR 4B in sales, more than making up for softness in the vaccine segment. Full breakdown here 👉 https://www.zacks.com/stock/news/2776468/sanofi-q3-earnings-beat-dupixent-drives-growth-as-vaccines-decline?cid=sm-stocktwits-2-2776468-teaser-17564&ADID=SYND_STOCKTWITS_TWEET_2_2776468_TEASER_17564
0 · Reply
smartoptionstrader
smartoptionstrader Oct. 24 at 4:37 PM
MAIN POST: Big Pharma's M&A wave isn't slowing—it's accelerating into 2026. $MRK $JNJ $SNY desperately plugging patent cliff revenue holes. But here's the smarter play: $GS collects fees on every deal. Trading at $781 (15.5x earnings, below $SPY average) and $44 off September highs, Goldman is positioned perfectly. Lower rates, desperate acquirers, and frozen IPOs lead to more deals, resulting in more GS fees. Don't gamble on which biotech gets bought—follow the money to Wall Street's M&A king. Goldman Sachs Long-Term Price Chart (1997-2025) - Shows a steady upward trajectory with a September 2025 record high at $825, currently trading at $781. The chart demonstrates GS's consistent performance across multiple market cycles, validating the bullish technical setup with clear upside potential to new highs.
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:50 PM
$SNY beats Q3 expectations — but why isn't the stock soaring? 🤔 Sanofi's Q3 results showed a 13.2% EPS increase at constant currency, beating the Zacks Consensus Estimate with Dupixent sales hitting over €4B for the first time. Yet, shares are only up 2% in pre-market trading. Discover why the market's lukewarm on SNY despite strong performance 👉 https://www.zacks.com/stock/news/2776468/sanofi-q3-earnings-beat-dupixent-drives-growth-as-vaccines-decline?cid=sm-stocktwits-2-2776468-body-17553&ADID=SYND_STOCKTWITS_TWEET_2_2776468_BODY_17553
0 · Reply
Diapers_Tequila
Diapers_Tequila Oct. 24 at 3:25 PM
$ALT Here is the link for the $SNY call this morning for everyone who missed it. https://www.youtube.com/watch?v=o6p0W4ZsLXw
2 · Reply
Jacked_Nicholson
Jacked_Nicholson Oct. 24 at 1:53 PM
$ALT @Designed2Gain $SNY $ €14-€15B
3 · Reply
GreenEnergy2022
GreenEnergy2022 Oct. 24 at 1:26 PM
$ALT Sounds like $SNY is looking for a best in class investment
1 · Reply
BTC321
BTC321 Oct. 24 at 12:53 PM
$NVAX $NVAX $SNY 🚀 Sanofi just reported strong positive results and mentioned Novavax in the same breath. The combo vaccines Fluzone HD + Nuvaxovid and Flublok + Nuvaxovid are already on the FDA Fast Track (US). 👉 If approved, this would be the first flu + COVID-19 protein vaccine — a potential game changer for both companies. Momentum is building. Volume next. 💥 #NVAX #SNY #FastTrack #Biotech #ShortSqueeze
1 · Reply
OpenOutcrier
OpenOutcrier Oct. 24 at 12:37 PM
$SNY (+2.1% pre) Sanofi (SNY) Tops Q3 EPS by 72c https://ooc.bz/l/81768
0 · Reply
Quantumup
Quantumup Oct. 24 at 11:26 AM
H.C. Wainwright reiterated $CDTX Buy/$150 after at the European Scientific Working Group on Influenza (ESWI)s 10th Influenza Conference, Cidara presented translational efficacy data on CD388, the company's lead influenza drug-Fc conjugate (DFC) candidate. $SNY $JNJ HCW in its note said:
0 · Reply
Elevate1
Elevate1 Oct. 24 at 11:09 AM
0 · Reply
cubie
cubie Oct. 23 at 7:58 PM
EARNINGS Before Bell SO PYB: $PG 140-$142S or 160-162S $GD 320 or 360 $HCA $400 OR 470 $ITW 240 or 270 $SNY 45s or 54s-$55
0 · Reply
Ersttr3der
Ersttr3der Oct. 23 at 6:38 PM
$DECK playing deck then $SNY ER!
0 · Reply
27R
27R Oct. 23 at 4:21 PM
$SNY Earnings release at before tomorrow open, significant post-earnings volatility with relatively reasonable implied volatility, perhaps consider a Straddle
0 · Reply
Gemini367
Gemini367 Oct. 23 at 12:27 PM
$VTYX Congrats to all, who are still invested. $10 on deck. With yesterdays news, buyout potential by $SNY and other big pharma players. Best of luck.
0 · Reply
clan
clan Oct. 22 at 7:39 PM
$MNKD How 'bout a deep dive on ULTRA Rapid-Acting mealtime insulin? None exists by $LLY $NVO nor $SNY , just by MannKind. #Afrezza
0 · Reply
ZacksResearch
ZacksResearch Oct. 22 at 3:01 PM
Breakthrough alert: $SNY just hit all key endpoints in its rare disease trial 🚀 Efdoralprin alfa met every primary goal in a global phase II study — positioning it as a potential first restorative recombinant therapy for AATD. Full story on what this means for Sanofi’s pipeline 👉 https://www.zacks.com/stock/news/2774232/snys-efdoralprin-alfa-meets-key-endpoints-in-rare-disease-study?cid=sm-stocktwits-2-2774232-teaser-17070&ADID=SYND_STOCKTWITS_TWEET_2_2774232_TEASER_17070
0 · Reply
ZacksResearch
ZacksResearch Oct. 22 at 2:01 PM
$SNY's efdoralprin alfa could revolutionize AATD treatment! 🚀 The phase II ElevAATe study met all primary and key secondary endpoints, showing significant improvements in functional AAT levels over current therapies. With FDA fast track and orphan drug designations, this candidate is one to watch. See what this means for Sanofi and AATD patients 👉 https://www.zacks.com/stock/news/2774232/snys-efdoralprin-alfa-meets-key-endpoints-in-rare-disease-study?cid=sm-stocktwits-2-2774232-body-17052&ADID=SYND_STOCKTWITS_TWEET_2_2774232_BODY_17052
0 · Reply
Quantumup
Quantumup Oct. 21 at 7:20 PM
Mizuho y'day🏁 $CLDX Outperform/$48 $NVS $REGN - $SNY JSPR $LLY TEVA ALLK Mizuho said: We are initiating coverage of Celldex Therapeutics with an Outperform rating and $48 PT as we see barzovolimab (anti-KIT mAb) as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. We believe barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit. With this, we performed probability modeling that we believe points to high probability of future statistical success in the ongoing Phase III trials for all-comers and the important subgroup of omalizumab-experienced patients, as well as clear opportunity to generate a best-in-indication efficacy profile. Altogether, we project $2.X.6B in risk-adjusted 2035 WW sales for barzolvolimab in chronic urticaria and expect positive Phase III data, as well as potential indication expansion to drive outperformance.
0 · Reply
Quantumup
Quantumup Oct. 20 at 6:46 PM
Piper Sandler reiterated $UPB Overweight-$75 and said UPB has traded up ~130%+ over the last 6-months where verekitug (TSLP-R mAb) showed compelling efficacy/safety in Ph2 VIBRANT CRSwNP with upcoming Ph2 VALIANT severe asthma topline 1Q26 (~Feb/Mar 2026, per our math). $AMGN - $AZN $REGN - $SNY Piper Sandler added:
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 20 at 12:47 PM
$COGT $BPMC $SNY we coming for the belt
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 20 at 10:02 AM
WATCHLIST OCT 20 2025 $NVO FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event $SNY AlphaMedix Shows Durable, Clinically Meaningful Responses In Advanced GEP-NETs, Meeting All Primary Endpoints In Phase 2 Study $IOBT IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance $PHAR Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases $STM STMicroelectronics Introduces Four New 5MP BrightSense Image Sensors For Industrial Automation, Security, And Smart Retail Applications
0 · Reply